Clinical Trial Update: A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes [Phase 2]

View source ↗

Summary

Phase 2 study evaluating flurpiridaz (18F) injection for PET imaging to assess myocardial perfusion quality, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease

Snippet

Sponsor: GE Healthcare | Conditions: Coronary Artery Disease (CAD), Ischemic Heart Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-08-01